Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac κ-opioid receptor stimulation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 4, 2009, Pages

  Bolte, Craig ^a   Newman, Gilbert ^a   Schultz, Jo El J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

( en dorphin; Cardiac function; Cardiac opioid receptors; Cardiac physiology; Hamsters; Hypertension

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; BETA ENDORPHIN; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DYNORPHIN A; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; LEUCINE ENKEPHALIN; METENKEPHALIN; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE DURATION; ESSENTIAL HYPERTENSION; EX VIVO STUDY; EXPERIMENTAL MODEL; HAMSTER; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZAMIDES; BETA-ENDORPHIN; BLOOD PRESSURE; CRICETINAE; CYCLIC AMP; DISEASE MODELS, ANIMAL; DYNORPHINS; ENKEPHALIN, LEUCINE; ENKEPHALIN, METHIONINE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; PIPERAZINES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; SYSTOLE; VENTRICULAR REMODELING;

EID: 66249110333     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00909.2008     Document Type: Article

References (61)

1. American Heart Association/American Stroke Association. Know the Facts, Get the Stats, 2007. [http://www.americanheart.org/downloadable/ heart/116861545709855-1041%20KnowTheFactsStats07-loRes.pdf].
2. Barlow MA, Deo S, Johnson S, Caffrey JL. Vagotonic effects of enkephalin are not mediated by sympatholytic mechanisms. Exp Biol Med (Maywood) 231: 387-395, 2006.
3. Barron BA. Cardiac opioids. Proc Soc Exp Biol Med 224: 1-7, 2000.
4. Beyer ME, Slesak G, Brehm BR, Hoffmeister HM. Hemodynamic and inotropic effects of the endothelin A antagonist BQ-610 in vivo. J Car- diovasc Pharmacol 31, Suppl 1: S258 -S261, 1998.
5. Beyer ME, Slesak G, Hovelborn T, Kazmaier S, Nerz S, Hoffmeister HM. Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610. Hypertension 33: 145-152, 1999.
6. Bhargava HN, Matwyshyn GA, Hanissian S, Tejwani GA. Opioid peptides in pituitary gland, brain regions and peripheral tissues of spontaneously hypertensive and Wistar-Kyoto normotensive rats. Brain Res 440: 333-340, 1988.
7. Braas KM, Hendley ED. Anterior pituitary proopiomelanocortin expression is decreased in hypertensive rat strains. Endocrinology 134: 196-205, 1994.
8. Caffrey JL, Boluyt MO, Younes A, Barron BA, O'Neill L, Crow MT, Lakatta EG. Aging, cardiac proenkephalin mRNA and enkephalin peptides in the Fisher 344 rat. J Mol Cell Cardiol 26: 701-711, 1994.
9. Chen-Izu Y, Chen L, Banyasz T, McCulle SL, Norton B, Scharf SM, Agarwal A, Patwardhan A, Izu LT, Balke CW. Hypertension-induced remodeling of cardiac excitation-contraction coupling in ventricular myo- cytes occurs prior to hypertrophy development. Am J Physiol Heart Circ Physiol 293: H3301-H3310, 2007.
10. Chen H, Azuma M, Maeda K, Kajimoto N, Higashino H. Impaired heart function and noradrenaline release after ischaemia in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 27: 664670, 2000.
11. Chen LB, Liu T, Wu JX, Chen XF, Wang L, Fan CL, Gao PJ, Higashino H, Lee WH, Yuan WJ, Chen H. Hypertonic perfusion reduced myocardial injury during subsequent ischemia and reperfusion in normal and hypertensive rats. Acta Pharmacol Sin24: 1077-1082, 2003.
12. Clark MJ, Harrison C, Zhong H, Neubig RR, Traynor JR. Endogenous RGS protein action modulates mu-opioid signaling through G.,o. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J Biol Chem278: 9418-9425, 2003.
13. Clo C, Muscari C, Tantini B, Pignatti C, Bernardi P, Ventura C. Reduced mechanical activity of perfused rat heart following morphine or enkephalin peptides administration. Life Sci37: 1327-1333, 1985.
14. Cozzolino D, Sasso FC, Cataldo D, Gruosso D, Giammarco A, Cavalli A, Di Maggio C, Renzo G, Salvatore T, Giugliano D, Torella R. Acute pressor and hormonal effects of beta-endorphin at high doses in healthy and hypertensive subjects: role of opioid receptor agonism. J Clin Endo- crinol Metab 90: 5167-5174, 2005.
15. de Simone G, Di Lorenzo L, Costantino G, Moccia D, Buonissimo S, de Divitiis O. Supernormal contractility in primary hypertension without left ventricular hypertrophy. Hypertension11: 457-463, 1988.
16. Deedwania PC. The progression from hypertension to heart failure. Am J Hypertens10: 280S-288S, 1997.
17. Douglas H, Kitchen I. Mechanisms involved in the cardiovascular responses to opioid products of proenkephalin in the anaesthetised rat. Gen Pharmacol23: 269-277, 1992.
18. Dumont M, Lemaire S. Increased content of immunoreactive Leu- enkephalin and alteration of delta-opioid receptor in hearts of spontaneously hypertensive rats. Neurosci Lett94: 114-118, 1988.
19. Feuerstein G, Siren AL. The opioid system in cardiac and vascular regulation of normal and hypertensive states.Circulation 75: I125-I129, 1987.
20. Fontana F, Bernardi P, Merlo Pich E, Boschi S, De Iasio R, Capelli M, Carboni L, Spampinato S. Endogenous opioid system and atrial natriuretic factor in normotensive offspring of hypertensive parents at rest and during exercise test. J Hypertens12: 1285-1290, 1994.
21. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension34: 782-789, 1999.
22. Gu H, Barron BA, Gaugl JF, Caffrey JL. Dynorphin, naloxone, and overflow of norepinephrine during cardiac nerve stimulation in dogs. Am J Physiol Heart Circ Physiol 263: H153-H161, 1992.
23. Gulati A, Artwohl JE, Kumar A, Gao XP, Rubinstein I. Endothelin- 1-like immunoreactivity in a new rodent model of spontaneous hypertension. Am J Hypertens 11: 866-869, 1998.
24. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 29: 28732892, 1997.
25. Hiranuma T, Iwao K, Kitamura K, Matsumiya T, Oka T. Almost complete protection from [Met5]-enkephalin-Arg6-Gly7-Leu8 (Met-enk- RGL) hydrolysis in membrane preparations by the combination of amasta- tin, captopril and phosphoramidon. J Pharmacol Exp Ther281: 769 -774, 1997.
26. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg135: 799 -808, 2008.
27. Isaka M, Imamura M, Sakuma I, Shiiya N, Ishizuka T, Ogata Y, Yasuda K. Experimental study of pegylated liposomal hemoglobin on norepinephrine release and reperfusion arrhythmias in isolated guinea pig hearts. Ann Thorac Cardiovasc Surg13: 391-395, 2007.
28. Koyuncuoglu H, Enginar N, Hatipoglu I. The in vitro and in vivo effects of enkephalins and beta-endorphin on ACE activity in mice. Pharmacol Res Commun 18: 301-309, 1986.
29. Kraft K, Theobald R, Kolloch R, Stumpe KO. Normalization of blood pressure and plasma concentrations of beta-endorphin and leucine-en- kephalin in patients with primary hypertension after treatment with clonidine. J Cardiovasc Pharmacol 10, Suppl 12: S147-S151, 1987.
30. Kraft KS, Behrendt M, Kolloch R, Stumpe KO.Reduced beta-endorphin secretion in young patients with mild essential hypertension at rest and during exercise. J Hypertens Suppl 6: S381-S383, 1988.
31. Krumins SA, Faden AI, Feuerstein G.Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun 127: 120-128, 1985.
32. Ku YH. Role of limbic peptidergic circuits in regulation of arterial pressure, relevant to development of essential hypertension. Neuropeptides 40: 299-308, 2006.
33. Kurjiaka DT. The conduction of dilation along an arteriole is diminished in the cremaster muscle of hypertensive hamsters. J Vasc Res 41: 517-524, 2004.
34. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40: 389-430, 2000.
35. Oudit GY, Crackower MA, Backx PH, Penninger JM.The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13: 93-101, 2003.
36. Peart JN, Gross ER, Headrick JP, Gross GJ. Impaired p38 MAPK/ HSP27 signaling underlies aging-related failure in opioid-mediated cardioprotection. J Mol Cell Cardiol 42: 972-980, 2007.
37. Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovasc Res 63: 414- 422, 2004.
38. Plobeck N, Delorme D, Wei ZY, Yang H, Zhou F, Schwarz P, Gawell L, Gagnon H, Pelcman B, Schmidt R, Yue SY, Walpole C, Brown W, Zhou E, Labarre M, Payza K, St-Onge S, Kamassah A, Morin PE, Projean D, Ducharme J, Roberts E. New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability. J Med Chem 43: 3878-3894, 2000.
39. Pugsley MK. The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system. Pharmacol Ther 93: 51-75, 2002.
40. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T. Pharmacological characterization of the cloned kappa-, delta-, and muopioid receptors. Mol Pharmacol 45: 330-334, 1994.
41. Romano MA, McNish R, Seymour EM, Traynor JR, Bolling SF. Differential effects of opioid peptides on myocardial ischemic tolerance. J Surg Res 119: 46-50, 2004.
42. Rossi F, Lampa E, Berrino L, Di Giaimo A, Marmo E. Central and peripheral cardiovascular effects of beta-endorphin in normotensive and spontaneously hypertensive rats and in rats rendered hypertensive by deoxycorticosterone acetate administration. Res Commun Chem Pathol Pharmacol55: 181-192, 1987.
43. Saeed RW, Stefano GB, Murga JD, Short TW, Qi F, Bilfinger TV, Magazine HI. Expression of functional delta opioid receptors in vascular smooth muscle. Int J Mol Med 6: 673-677, 2000.
44. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther 89: 123-137, 2001.
45. Schutte F, Burgdorf C, Richardt G, Kurz T. Adenosine A1 receptor- mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can J Physiol Pharmacol84: 573-577, 2006.
46. Silva CO, Monteiro-Filho WO, Duarte GP, Lahlou S. Effects of long-term pretreatment with isoproterenol on inotropic responsiveness to alpha-adrenoceptor stimulation: study in isolated perfused rat hearts. J Pharm Pharmacol53: 233-242, 2001.
47. Standifer KM, Pasternak GW.G proteins and opioid receptor-mediated signalling. Cell Signal 9: 237-248, 1997.
48. Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 59: PL331-PL336, 1996.
49. Thomas CL, Artwohl JE, Suzuki H, Gao X, White E, Saroli A, Bunte RM, Rubinstein I. Initial characterization of hamsters with spontaneous hypertension. Hypertension 30: 301-304, 1997.
50. Ventura C, Bastagli L, Bernardi P, Caldarera CM, Guarnieri C.Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta 987: 69-74, 1989.
51. Ventura C, Pintus G, Tadolini B. Opioid peptide gene expression in the myocardial cell. TCM 8: 102-110, 1998.
52. Ventura C, Guarnieri C, Bastagli L, Bernardi P, Puddu P, Caldarera CM. Calcium stimulates opioid receptor agonism in rat cardiac sarcolemma. Cardioscience 1: 151-154, 1990.
53. Ventura C, Muscari C, Spampinato S, Bernardi P, Caldarera CM. Effects of naloxone on the mechanical activity of isolated rat hearts perfused with morphine or opioid peptides. Peptides8: 695-699, 1987.
54. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P.Hydrolysis of biological peptides by human angiotensin- converting enzyme-related carboxypeptidase. J Biol Chem277: 14838 - 14843, 2002.
55. Wenzlaff H, Stein B, Teschemacher H. Diminution of contractile response by kappa-opioid receptor agonists in isolated rat ventricular car- diomyocytes is mediated via a pertussis toxin-sensitive G protein. Naunyn Schmiedebergs Arch Pharmacol358: 360-366, 1998.
56. Wintzen M, Ostijn DM, Polderman MC, le Cessie S, Burbach JP, Vermeer BJ. Total body exposure to ultraviolet radiation does not influence plasma levels of immunoreactive beta-endorphin in man. Photodermatol Photoimmunol Photomed17: 256-260, 2001.
57. Xiao RP, Spurgeon HA, Capogrossi MC, Lakatta EG. Stimulation of opioid receptors on cardiac ventricular myocytes reduces L type Ca2+ channel current. J Mol Cell Cardiol25: 661-666, 1993.
58. Zakrzeska A, Schlicker E, Kwolek G, Kozlowska H, Malinowska B. Positive inotropic and lusitropic effects mediated via the low-affinity state of beta1-adrenoceptors in pithed rats. Br J Pharmacol146: 760-768, 2005.
59. Zheng X, Zhang T, Ding H, Wang C. Plasma levels of beta-endorphin, leucine enkephalin and arginine vasopressin in patients with essential hypertension and the effects of clonidine. Int J Cardiol51: 233-244, 1995.
60. Zimlichman R, Gefel D, Eliahou H, Matas Z, Rosen B, Gass S, Ela C, Eilam Y, Vogel Z, Barg J. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation93: 10201025, 1996.
61. Zugck C, Lossnitzer D, Backs J, Kristen A, Kinscherf R, Haass M. Increased cardiac norepinephrine release in spontaneously hypertensive rats: role of presynaptic alpha-2A adrenoceptors. J Hyperten21: 13631369, 2003.